2seventy bio, Inc.

NasdaqGS:TSVT Stock Report

Market Cap: US$162.0m

2seventy bio Management

Management criteria checks 0/4

2seventy bio's CEO is Chip Baird, appointed in Apr 2024, has a tenure of less than a year. total yearly compensation is $2.93M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $186.56K. The average tenure of the management team and the board of directors is 0.7 years and 1.3 years respectively.

Key information

Chip Baird

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage17.7%
CEO tenureless than a year
CEO ownership0.1%
Management average tenureless than a year
Board average tenure1.3yrs

Recent management updates

Recent updates

2seventy bio: All In On Abecma Multiple Myeloma Treatment

Dec 23

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

Nov 15
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04
2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06
2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17
Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13
2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05
Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21
Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19
2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

Oct 04
We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

Sep 08

2seventy bio Prospects

Aug 23

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12
Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

CEO Compensation Analysis

How has Chip Baird's remuneration changed compared to 2seventy bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$95m

Jun 30 2024n/an/a

-US$156m

Mar 31 2024n/an/a

-US$223m

Dec 31 2023US$3mUS$518k

-US$218m

Sep 30 2023n/an/a

-US$184m

Jun 30 2023n/an/a

-US$180m

Mar 31 2023n/an/a

-US$215m

Dec 31 2022n/an/a

-US$254m

Sep 30 2022n/an/a

-US$292m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$291m

Dec 31 2021US$2mUS$491k

-US$292m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$320m

Mar 31 2021n/an/a

-US$222m

Dec 31 2020US$2mUS$475k

-US$120m

Compensation vs Market: Chip's total compensation ($USD2.93M) is above average for companies of similar size in the US market ($USD1.41M).

Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.

CEO

Chip Baird (52 yo)

less than a year

Tenure

US$2,927,118

Compensation

Mr. William D. Baird III, also known as Chip, serves as Chief Executive Officer, President and Director of 2seventy bio, Inc. since April 1, 2024. He was Principal Financial Officer and Principal Accountin...

Leadership Team

NamePositionTenureCompensationOwnership
William Baird
CEO, President & Directorless than a yearUS$2.93m0.12%
$ 186.6k
Victoria Eatwell
Chief Financial Officerless than a yearno data0.66%
$ 1.1m
Jessica Snow
Senior VP of Quality and Head of Operationsless than a yearno data0.30%
$ 481.9k

0.7yrs

Average Tenure

45yo

Average Age

Experienced Management: TSVT's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Baird
CEO, President & Directorless than a yearUS$2.93m0.12%
$ 186.6k
Eli Casdin
Independent Directorless than a yearno datano data
Nick Leschly
Chairman of the Boardless than a yearUS$9.08m1.43%
$ 2.3m
Charles Newton
Independent Directorless than a yearno datano data
Marcela Maus
Independent Director3.2yrsUS$290.00k0.023%
$ 36.7k
Denice Torres
Lead Independent Director3.2yrsUS$304.00k0.038%
$ 61.3k
Sarah J. Glickman
Independent Director3.2yrsUS$303.00k0.028%
$ 45.8k
Wei Lin
Independent Director1.8yrsUS$622.05k0.019%
$ 30.6k

1.3yrs

Average Tenure

53yo

Average Age

Experienced Board: TSVT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:36
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

2seventy bio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Samantha Lynn SemenkowCitigroup Inc
Samantha Lynn SemenkowCitigroup Inc